Landon Cameron, DPM
Podiatrist · Mesquite, NVNPI 1598119463
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 67 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Smith+Nephew at 39.4% of the total. Reporting peaked in 2022 at $423 and has fallen 72.4% since, to $117 in 2025.
Across 67 payments — averaging $19.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$510
- Acera Surgical, Inc.$404
- ANI Pharmaceuticals, Inc.$66
- Medtronic$48
- Amgen$44
- Orthofix Medical, Inc.$28
- plus $194 from 12 others
What the payments were for
- Food & beverage$1,294100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 26 | $510 |
| Acera Surgical, Inc. | 19 | $404 |
| ANI Pharmaceuticals, Inc. | 3 | $66 |
| Medtronic(2 entities) | 3 | $48 |
| Amgen(2 entities) | 2 | $44 |
| Orthofix Medical, Inc. | 1 | $28 |
| KCI USA, Inc. | 2 | $27 |
| GRT US Holding, Inc. | 1 | $19 |
| Novo Nordisk | 1 | $19 |
| Solventum Corporation | 1 | $17 |
| Treace Medical Concepts, Inc. | 1 | $17 |
| Hydrocision, Inc. | 1 | $17 |
| Integra Lifesciences Corporation | 1 | $14 |
| Innocoll Pharmaceuticals Limited | 1 | $14 |
| Organogenesis Inc. | 1 | $13 |
| Tactile Systems Technology Inc | 1 | $13 |
| Bioventus LLC | 1 | $12 |
| Bsn Medical Inc | 1 | $12 |
How this compares
$1,294 in reported general payments places this provider in the 60th percentile of 44 podiatrist providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 86 | $1,512 |
| Meloxicam | 52 | $388 |
| Cephalexin | 37 | $354 |
| Terbinafine Hcl | 28 | $311 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 22 | $210 |
| Ciprofloxacin Hcl | 17 | $192 |
| Clindamycin Hcl | 11 | $168 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 17 | $111 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 18 | $90 |
Paid to pharmacies, not to this prescriber.
Other podiatrist in Mesquite
- Anthony RicciardiLas Vegas$498K
- Jeremy AndersonLas Vegas$72K
- He XuLas Vegas$54K
- Stuart FeldmanHenderson$34K
- Blake SavageHenderson$18K
- Peter BregmanLas Vegas$18K
- Anmy VuLas Vegas$15K
- Ai Quoc HellerLas Vegas$8K
- John CadeLas Vegas$6K
- Ada VeraLas Vegas$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.